Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 2Active not recruiting 2Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Recurrence 1Neurofibrosarcoma 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioblastoma 1Dermatofibrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Nonhematological Neoplasms 1

Interventions

Carboplatin 49Pemetrexed 38Cisplatin 34Radiotherapy 32Docetaxel 31Gemcitabine 25Paclitaxel 24Nivolumab 18pembrolizumab 15Etoposide 15Radiosurgery 13Erlotinib Hydrochloride 11Bevacizumab 11Magnetic Resonance Spectroscopy 10Vinorelbine 9Radiation 9Cyclophosphamide 7durvalumab 6Gefitinib 6Fluorodeoxyglucose F18 6Celecoxib 6atezolizumab 5Oxaliplatin 5Irinotecan 5Immunoglobulin G 5Drug Therapy 5Disulfides 5Dexamethasone 5Chemotherapy, Adjuvant 5vandetanib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lung Neoplasms × sapanisertib × Clear all
NCT05275673 2025-04-24

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Faeth Therapeutics

Phase 2 Terminated
7 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡